about
Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myelomaDeregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitorsGenomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survivalManaging incidental findings and research results in genomic research involving biobanks and archived data sets.High-order SNP combinations associated with complex diseases: efficient discovery, statistical power and functional interactions.Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.Interaction of CYP1B1, cigarette-smoke carcinogen metabolism, and lung cancer risk.Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.Returning a Research Participant's Genomic Results to Relatives: Analysis and Recommendations.Returning a Research Participant's Genomic Results to Relatives: Perspectives from Managers of Two Distinct Research Biobanks.Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.Genomic research and incidental findings.Managing incidental findings in human subjects research: analysis and recommendations.Return of individual research results and incidental findings in the clinical trials cooperative group setting.Mapping the inputs, analyses, and outputs of biobank research systems to identify sources of incidental findings and individual research results for potential return to participants.The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.Applications and limitations in translating genomics to clinical practice.Downstream effectors of oncogenic ras in multiple myeloma cells.Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.A de novo splice site mutation in EHMT1 resulting in Kleefstra syndrome with pharmacogenomics screening and behavior therapy for regressive behaviors.The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype.Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice.Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.Clinical and biologic implications of recurrent genomic aberrations in myeloma.
P50
Q28534703-E065B09E-DE05-4EBD-97FD-5002765601E0Q30436741-1C960F63-D8D0-44A1-A583-994F40FC7A2BQ33367792-1414FE6C-D2E0-4347-AC81-2DB61FCDADB2Q34205284-F57A8B46-6EBA-481F-9A6F-3A19123808E0Q34247032-2BD508AE-DA0A-4321-BEEA-FFEAA41161A4Q34380431-47B2FEFE-0528-4673-8B0B-48DFFF5CE03EQ34793998-D019B7B9-D213-423F-A760-7CBFEC2FB1B4Q35606328-DFB24BB7-1731-4AD7-AD2C-A89A3A48D531Q36197112-FC883AF7-32AF-4FB5-8D54-17F3AEC95D2BQ36198396-A4FE24E5-141E-4F17-B67D-190883AEC496Q36238764-0893A505-06BF-4814-9A6E-650518B95ED4Q36697556-6887CE71-A4E7-438E-A587-9C26CBED75CBQ36944452-9CD2D4B7-C610-4C50-8C3E-D3825D653823Q36954360-E4E37098-4471-4C17-9698-49DBD117054EQ37016795-238749FB-B780-4BF4-A007-2FA8743B5C1CQ37125650-15522FBE-90F2-4F47-9175-587D3DEBBC46Q37458231-DE2FE0DD-B8A2-4EBD-BB5E-B839369AA744Q38498307-AA0D6D7E-CBB4-4B32-9CA0-5B9A423065C0Q40679257-F0A749BC-3A6A-46B0-BC58-F8CA7EE1108FQ40683311-8F4F94C9-8E9C-424E-AA58-2E647BF86D96Q42293521-3C62017A-A5BE-4578-AE1E-B8EDCABF3EE6Q42812559-057DF455-8508-4FF0-8F34-3D9007625BC1Q43504310-C83919F1-8E1A-4634-991D-AF954113726EQ44376673-F40486F1-439A-43DE-92C6-3B5180A5DE4BQ44383699-4D079234-5679-497C-B9C4-6B28662196C2Q44776402-A0835C9F-A497-43D0-ADB5-726E6C76D51D
P50
description
onderzoeker
@nl
name
Brian Van Ness
@ast
Brian Van Ness
@en
Brian Van Ness
@es
Brian Van Ness
@nl
Brian Van Ness
@sl
type
label
Brian Van Ness
@ast
Brian Van Ness
@en
Brian Van Ness
@es
Brian Van Ness
@nl
Brian Van Ness
@sl
prefLabel
Brian Van Ness
@ast
Brian Van Ness
@en
Brian Van Ness
@es
Brian Van Ness
@nl
Brian Van Ness
@sl